Ultimate magazine theme for WordPress.

Medical Cannabis Pharmacogenomics and Drug Interactions


Presented At:
LabRoots – Cannabis Sciences Virtual Event 2019

Presented By:
Jahan Marcu, PhD – Co-Founder, Chief Operations Officer, Director of Experimental Pharmacology and Behavioral Research, International Research Center on Cannabis Mental Health

Speaker Biography:
Jahan Marcu, Ph.D., is currently the Chief Science Officer at Americans for Safe Access (a medical cannabis advocacy non-profit) and Director of the Patient Focused Certification program, which is a health and safety oversight program that assesses regulatory compliance at cannabis operations. He is co-founder and past-chairman of the CANN subdivision of the Chemical Health and Safety Division (DCHAS) of the American Chemical Society. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine. He has a background in analytical chemistry and molecular pharmacology, he received his Ph.D. for contributions in characterizing the structure and function of the cannabinoid receptors.

Medical Cannabis Pharmacogenomics and Drug Interactions

Webinar Abstract:
The therapeutic applications of medical cannabis and cannabinoid drugs is controversial, however the number of medical conditions in which cannabinoids and cannabis have shown promise as therapeutic treatments is expanding. The occurrence of side effects from cannabinoids is still a concern, especially with the wide variability in drug levels and response that has been observed. This is compounded by possible interactions with prescription drugs. Application of pharmacogenomics (PGx) and knowledge of drug-drug interactions could help patients and doctors navigate the complexities of combining prescription drugs and cannabis compounds. Genetic variants in several drug metabolizing enzymes may impact response to cannabinoids, including CYP3A4, CYP2C9, and CYP2C19. Furthermore, drug interactions caused by cannabinoids may also be mediated by drug metabolizing enzymes (e.g. CYP2C9, CYP2D6, CYP2B6, CYP1A1) and possibly drug transporters such as ABCB1. Understanding how commonly prescribed drugs and cannabinoids interact could help reduce risks associated with polydrug regimens. This presentation will discuss PGx testing for cannabis and potential impacts on commonly prescribed pharmaceuticals.

Learning Objectives:
1. Be able to discuss CYPs involved with cannabinoid metabolism
2. Know potential risks associated with oral CBD administration

Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/cannabis-sciences-2019)
2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/virtual-event/cannabis-sciences-2019)
3. Click Here to get your PACE credits (Expiration date – March 28, 2021 06:00 AM): https://www.labroots.com/credit/pace-credits/3406/third-party

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc



Leave A Reply

Your email address will not be published.